PACK CHECK · MARKET FIRST

MICROZIDEGeneric namehydrochlorothiazide

How this medicine works

The FDA label explains that hydrochlorothiazide blocks part of sodium and chloride reabsorption, increasing sodium and water excretion. It may also increase loss of potassium, hydrogen and chloride and affect calcium and uric-acid excretion. This is why blood pressure alone is not enough: symptoms, kidney function and electrolyte monitoring also matter.

Read source: United States ↗reviewed 2026-08-29More about its action and precautions →

Check the market, names, dosage form and route together

A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.

Open the complete product-identity record

Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.

International brand name: MICROZIDE
Source-scoped market brand names: MICROZIDE · United StatesCurrent regulator record ↗
Current FDA Orange Book data: NDA 020504, hydrochlorothiazide 12.5 mg oral capsule, prescription RLD/RS; an exact current NDC and pack were not established in this review.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
Generic name: hydrochlorothiazide
Dosage-form class: Hydrochlorothiazide 12.5 mg oral capsule; not a hydrochlorothiazide tablet or a combination tablet that already contains hydrochlorothiazide
Route: Oral
Package-image status: A source-linked public label image is available below

No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.

FOR EVERYDAY QUESTIONS

After the leaflet, continue with the question you still need to check

What this pack is

MICROZIDE is the brand name in this record; hydrochlorothiazide is the generic name. Read both together with the dosage form (oral capsule).

What this page can show

This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.

What to bring to the next conversation

Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.

NEXT SAFE STEP

Choose the next safe check

A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →

PRODUCT PRESENTATION IDENTITY

Strength, pack and device identity

Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.

How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.

1 source-backed strength, pack or device records — open the full list

First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.

United States label · Historical U.S. DailyMed label (revised Oct 2011; marketing for this NDC ended 31 Aug 2020)

Hydrochlorothiazide 12.5 mg per capsule; 100-capsule bottle (historical pack)

Product code: NDC 52544-622-01
Form and route: MICROZIDE hydrochlorothiazide hard-gelatin oral capsule · oral (historical product-identity field)
Container: bottle (historical)
Listing review: Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
hydrochlorothiazide: 12.5 mghistorical labelled amount per capsule; not an individual's capsule count, frequency or missed-use instruction
Package: 100 capsules per bottle
Labelled appearance: teal opaque · two-piece size 4 hard-gelatin capsule; unscored · imprint MICROZIDE / 12.5 mgCapsule; tablet score status does not apply

Open the presentation source ↗reviewed 2026-08-29

PUBLIC LABEL IMAGE

Appearance and package-text clues

This dated or historical public-label image is for checking the brand, generic-name, strength and dosage-form clues only. It does not authenticate a product or establish originator status, a current label, current packaging, target-market approval or sale eligibility.

Open the public label source ↗

LABEL READING · NOT A PRESCRIPTION

MICROZIDE label reading: check combination-product duplication first, then fluid and electrolyte signals

Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.

MICROZIDE is a hydrochlorothiazide capsule labelled 12.5 mg per capsule. The 12.5 mg is a product-identity amount, not this site's recommended capsule count, and the same ingredient may also be present inside a combination blood-pressure medicine.

Read the active ingredients on every pack. AVALIDE already contains irbesartan/hydrochlorothiazide, while EXFORGE HCT contains amlodipine/valsartan/hydrochlorothiazide. If MICROZIDE or another HCTZ product is also on the full list, ask a pharmacist or prescriber to check for duplication; do not stop one yourself.
Dry mouth, marked thirst, weakness, drowsiness, restlessness, muscle pain or cramps, fast heartbeat, dizziness, clearly reduced urine, persistent nausea or vomiting may accompany fluid or electrolyte changes. Seek local emergency help for severe or sudden symptoms, fainting or altered consciousness.
Older adults, kidney or liver impairment, gout or high urate, diabetes, and co-use of other blood-pressure medicines, digoxin, corticosteroids, lithium, pain or anti-inflammatory medicines, or alcohol all require review of the exact packs and complete medicine list. The site does not generate an adjustment from age, laboratory or blood-pressure numbers.
Sudden eye pain, rapid loss of vision or marked blurred vision needs prompt medical assessment. Swelling of the face, lips, tongue or throat, breathing difficulty or a severe skin reaction requires local emergency services. Do not wait for the website to decide whether the medicine caused it.
The dated FDA label advises sun protection and regular skin checks as clinically directed during long-term use. This does not mean a user will develop skin cancer and is not a reason to stop treatment independently; seek professional assessment for a new, changing, bleeding or non-healing skin lesion.

Open this record's official electronic leaflet ↗

PHARMACOVIGILANCE · OFFICIAL ROUTES

Check safety information in the right market

Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.

Match five details before using a safety record

Brand and generic nameBoth must match the medicine named by the record.
Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
Market and notice dateA record applies only to the country or region and date it names.
Lot, pack and manufacturerRecord these only when the official notice specifically names them.
Current product informationA historical record may have been superseded by the current label.

This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.

This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-08-29

This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.

Markets actually represented by the reviewed product documents

United States · 3

This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.

This record’s label or product-record routeFDA: U.S. prescribing information for MICROZIDE (hydrochlorothiazide) 12.5 mg capsules (revised Aug 2020; label states it may not be the latest version) ↗reviewed 2026-08-29

Global official safety gateways

NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22

This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.

For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.

PRIVATE FAMILY LIST

Bring this record into a local medicine list

Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.

Add to the family medicine list →

PACK · LABEL · MEDICINE LIST

Six checks for this medicine pack

Use this card to organise questions about MICROZIDE (hydrochlorothiazide). Keep the exact pack, its current label and the full medicine list together.

Identify the exact product
MICROZIDE is the brand in this record and hydrochlorothiazide is the active-ingredient name. Check both with the dosage form (Hydrochlorothiazide 12.5 mg oral capsule; not a hydrochlorothiazide tablet or a combination tablet that already contains hydrochlorothiazide) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.

This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.

Add this product identity to the private medicine list →Read the everyday label guide →Open the official electronic leaflet for this record ↗FDA tablet-splitting guidance ↗FDA medicine-list guidance ↗FDA pharmacogenetic association table ↗

MARKET DOCUMENTS · READ SEPARATELY

Enlarged market leaflets and regulator documents

Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.

HOW IT WORKS · NOT A TREATMENT PLAN

How hydrochlorothiazide works: reducing sodium and chloride reabsorption so more water leaves in urine

It is not an ordinary water-removal capsule or a tool to increase or repeat yourself because swelling, weight or blood pressure changes. Excessive diuresis can cause dehydration, low blood pressure and electrolyte disturbance.
Hydrochlorothiazide tablets, MICROZIDE capsules and combination tablets containing hydrochlorothiazide are different products. A shared ingredient does not permit self-combination, rotation, splitting or substitution by milligram numbers.
The site explains the pharmacologic pathway and label risks. It does not decide an individual's target blood pressure, timing, capsule count, missed-use action, fluid or salt intake, laboratory frequency, stopping or switching.

Open the primary pharmacology source ↗

SOURCE EVIDENCE REGISTER

Source evidence map

Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.

SOURCE-TRACEABLE ARCHIVE

MICROZIDEhydrochlorothiazide

This page links to public primary-source material for MICROZIDE. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.

DOCUMENT TIMELINE

Document timeline

1996-12-27
FDA original approval
Current Orange Book data link the MICROZIDE 12.5 mg oral capsule to NDA 020504 and RLD/RS identity.
FDA Orange Book current data: MICROZIDE (hydrochlorothiazide), NDA 020504, 12.5 mg oral capsule; prescription RLD and RS ↗
2020-08
Dated FDA prescribing-information revision
This document supports enlarged label reading here; it says it may not be the latest approved label and therefore does not alone establish a current pack or every current statement.
FDA: U.S. prescribing information for MICROZIDE (hydrochlorothiazide) 12.5 mg capsules (revised Aug 2020; label states it may not be the latest version) ↗
2020-08-31
Historical DailyMed NDC marketing end
The NDC 52544-622-01 100-capsule bottle image is used only as a historical pack reference after this date.
DailyMed (NLM): historical label for MICROZIDE 12.5 mg, NDC 52544-622-01, 100-capsule bottle (revised Oct 2011; marketing ended 31 Aug 2020) ↗

MARKET SCOPE

Market-record boundary

United States

Currently listed by the Orange Book as prescription RLD/RS; exact current NDC/pack not established

The page retains product identity while marking the 2020 label and old pack as dated material; it does not establish pharmacy stock or purchasing eligibility.

Mainland China and other markets

Current market record not established

No local approval, trade name, pack, originator/generic relationship, supply or interchangeability is inferred from the U.S. name, generic or 12.5 mg number.

How to read this record

Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.

Keep international and mainland China records separate

This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.

CDE listed-drug directory ↗　NMPA public query ↗

RECORD FAQ

Record questions

Why should combination medicines be checked carefully?

Hydrochlorothiazide may already be listed as the second or third ingredient on a combination pack. Adding MICROZIDE may duplicate that ingredient, but only the exact prescriptions and full medicine list can show whether this is duplication or intentional; the website cannot tell you to stop a pack.

Does 12.5 mg mean one capsule must be taken each time?

No. The 12.5 mg is the labelled amount per capsule for product identification. An individual's capsule count, frequency, missed-use action and adjustment require professional review of the prescription, condition, kidney function, electrolytes and other medicines.

Is the teal capsule image the appearance of a pack available now?

No. The image corresponds to NDC 52544-622-01 in a 2011 DailyMed historical label whose marketing ended in 2020. A current pack must be checked separately using all visible text, NDC or approval information and the target market's official record.

Evidence status

The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.

RECORD AT A GLANCE

Area: Cardiovascular
Archive identifier: FDA NDA 020504 (MICROZIDE / hydrochlorothiazide 12.5 mg oral capsule)
Archive market: United States: current FDA Orange Book data list MICROZIDE, hydrochlorothiazide 12.5 mg, oral capsule, NDA 020504 and prescription RLD/RS status. The page separately cites a 2020 FDA label and an exact 2011 DailyMed pack whose marketing has ended; it does not present an old NDC or old pack as current.
Dosage form: Hydrochlorothiazide 12.5 mg oral capsule; not a hydrochlorothiazide tablet or a combination tablet that already contains hydrochlorothiazide
Route: Oral
Record status: Source-traceable archive
U.S. initial approval: 1996
Source/archive entity: Teva Branded Pharmaceutical Products R&D LLC (applicant listed in current FDA Orange Book data)Identifies the source for this page or an entity named in a historical document; it is not a current holder or manufacturer conclusion.
Last reviewed: 2026-08-29

Primary sources

Always check the current label and the relevant professional advice in the intended market.

EDITORIAL RECORD

Who prepared and checked this page

Byline: OriginDrug Content Editorial
Review role: Public primary-source verification
Last reviewed: 2026-08-29
Source record: 3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.